Intended Audience: PCPs (including APP), Internal Medicine (including APP), Cardiologist (including APP), Nephrologist (including APP), Endocrinologist (including APP), PharmDs (including APP)

Educational Need:

CKM (Cardio-Kidney-Metabolic) syndrome represents an evolving area of clinical care. Clinicians require education on CKM definition and staging, interrelated pathophysiology, and evidence-based therapies that provide both cardiac and kidney benefits.

Bayer TA Rationale for Educational Support:

• Promote understanding of CKM Syndrome framework
  • Definition of CKM syndrome and stages
  • Discussion of CKM pathophysiology interconnections
  • Therapies with cardio-kidney benefits
• Educate clinicians on:
  • Tools for predicting risk of CV events (UACR, eGFR, PREVENT etc.)
  • The importance of UACR as a risk factor/predictor for CV events
  • Alignment with current AHA CKM guidelines
  • Practical strategies for applying evidence-based therapies in clinical practice

Preferred Format:

• Enduring
• Downloadable slides
• Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
• Podcast
• Live Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning Objectives
• Proposed Faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan
• Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References:

Publication References

1. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Després JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, Sperling LS, Virani SS, Wright JT, Rajgopal Singh R, Elkind MSV, Rangaswami J; American Heart Association. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation. 2023 Nov 14;148(20):1636-1664.
2. Ostrominski JW, Harrington J, Claggett BL, Filippatos G, Desai AS, Jhund PS, Henderson AD, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, Brinker MD, Rohwedder K, Lay-Flurrie J, Lage A, McMurray JJV, Solomon SD, Vaduganathan M. Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. J Am Coll Cardiol. 2025 Nov 18;86(20):1781-1801.
3. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484. Erratum in: Eur Heart J. 2022 May 21;43(20):1989.
4. Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, Brinker M, Kolkhof P, Schloemer P, Lay-Flurrie J, Viswanathan P, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Rossing P, Ruilope LM, Anker SD, Pitt B, Agarwal R, McMurray JJV, Solomon SD. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024 Dec;30(12):3758-3764. doi: 10.1038/s41591-024-03264-4. Epub 2024 Sep 1. Erratum in: Nat Med. 2024 Dec;30(12):3778.